A role for 5-HT(2C) receptor antagonists in the treatment of Parkinson's disease?

Drug News and Perspectives

Volumn 12, Issue 8, 1999, Pages 477-483

  Fox, S H ^a   Brotchie, J M ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; NORCLOZAPINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

BASAL GANGLION; BONE MARROW SUPPRESSION; DOPAMINERGIC TRANSMISSION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GLOBUS PALLIDUS; HUMAN; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

EID: 0032692213     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.1999.12.8.658766     Document Type: Review

References (81)